Comanche Biopharma

Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational small interfering RNA (siRNA) therapy for the treatment of preeclampsia. Preeclampsia is a severe pregnancy complication characterized by high blood pressure and organ damage, affecting up to 8% of pregnancies worldwide. It leads to approximately 80,000 maternal and 500,000 fetal and newborn deaths globally each year.

CBP-4888 is a subcutaneously delivered siRNA therapeutic that targets soluble fms-like tyrosine kinase-1 (sFlt1), a protein overproduced by the placenta in preeclampsia. This excess sFlt1 enters the mother's bloodstream, causing vascular damage and the symptoms of preeclampsia. By reducing sFlt1 production in the placenta, CBP-4888 aims to ameliorate preeclampsia symptoms like high blood pressure and organ damage, potentially enabling safer prolongation of pregnancy.

In August 2023, CBP-4888 received Fast Track designation from the US FDA for sFlt1-mediated pre-term preeclampsia. Comanche completed a Phase 1 trial in healthy volunteers and received FDA clearance for an Investigational New Drug application in March 2023. In January 2024, the company secured USD 75 million in oversubscribed Series B financing to initiate a clinical study of CBP-4888 in pregnant preeclamptic patients later that year.